Skip to main content
Premium Trial:

Request an Annual Quote

Other Uses

The mRNA vaccine technology behind some of the authorized SARS-CoV-2 vaccines is also being applied to other diseases, including cancer, CBS Sunday Morning reports.

"We've had an incredible year using messenger RNA to fight a pandemic," Stephen Hoge, the president of Moderna, tells it. "But we think we're just starting in the infectious disease space. And so, there's a large number of other vaccines we're bringing forward."

As CBS Sunday Morning notes, the company is pursuing a vaccine for HIV, aims to streamline the process for making influenza vaccines, and is also developing vaccines for cancers like lymphoma and melanoma. One, for melanoma, is in clinical testing, it adds. BioNTech, which worked with Pfizer on their mRNA-based SARS-CoV-2 vaccine, is similarly seeking to expand its repertoire and is working on a tuberculosis and an HIV vaccine, as the Financial Times noted earlier this month.

At the same time, Moderna is also working on SARS-CoV-2 boosters, which CBS Sunday Morning says it is considering – if boosters are indeed needed – rolling that together with its flu vaccine so that people only need one shot.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.